Your browser doesn't support javascript.
loading
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo, Miren; Arasanz, Hugo; Fernández-Hinojal, Gonzalo; García-Granda, Maria Jesus; Gato, María; Bocanegra, Ana; Martínez, Maite; Hernández, Berta; Teijeira, Lucía; Morilla, Idoia; Lecumberri, Maria Jose; Fernández de Lascoiti, Angela; Vera, Ruth; Kochan, Grazyna; Escors, David.
Afiliación
  • Zuazo M; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Arasanz H; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Fernández-Hinojal G; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • García-Granda MJ; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Gato M; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Bocanegra A; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Martínez M; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Hernández B; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Teijeira L; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Morilla I; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Lecumberri MJ; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Fernández de Lascoiti A; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Vera R; Department of Oncology, Hospital Complex of Navarre, IdISNA, Pamplona, Spain.
  • Kochan G; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
  • Escors D; Immunomodulation Group, Biomedical Research Center of Navarre-Navarrabiomed, Fundación Miguel Servet, IdISNA, Pamplona, Spain.
EMBO Mol Med ; 11(7): e10293, 2019 07.
Article en En | MEDLINE | ID: mdl-31273938
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Inmunidad Celular / Memoria Inmunológica / Inmunoterapia / Neoplasias Pulmonares / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Inmunidad Celular / Memoria Inmunológica / Inmunoterapia / Neoplasias Pulmonares / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article